Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 3.01, 7.01, 8.01, 9.01 · 8-K

Medicus Pharma Ltd.

MDCXNASDAQEQUITYCurrent

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD Disclosure · Other Events

Item 8.01. Other Events. On November 18, 2026, the Company received the Conditional Compliance Notice from the Listing Qualifications Department of Nasdaq notifying the Company that the deficiency relating to the minimum Market Value of Listed Securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) had been lifted because the Company had demonstrated compliance with the alternative mini…

Filed Nov 19, 2026Accepted Nov 19, 2026, 7:57 AM ESTCIK 1997296Accession 0001062993-26-006190
Share

Company context

We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and  accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are  developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").

Current securities

Recent company filings

  1. 424B3 filingNov 19, 2026
  2. SCHEDULE 13D/A - filed by Bokhari Raza regarding Medicus Pharma Ltd.Nov 17, 2026
  3. 4 filingNov 17, 2026
  4. 4 filingNov 17, 2026
  5. 4 filingNov 17, 2026

Registered securities in this filing

Medicus Pharma Ltd. · 8-K · Filed 2026-11-19

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common shares, no par value

Symbol
MDCX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: CR20261118_dei_EntityListingsExchangeAxis_exch_XNCM_us-gaap_StatementClassOfStockAxis_mdcx_CommonSharesNoParValueMember

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants, exercisable for common shares

Symbol
MDCXW
Exchange
NASDAQ
Classification
WARRANT
Status
Current
Filing context

Context: CR20261118_dei_EntityListingsExchangeAxis_exch_XNCM_us-gaap_StatementClassOfStockAxis_mdcx_WarrantsExercisableForCommonSharesMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000106299326006190 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 3.01, 7.01, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events. On November 18, 2026, the Company received the Conditional Compliance Notice from the Listing Qualifications Department of Nasdaq notifying the Company that the deficiency relating to the minimum Market Value of Listed Securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) had been lifted because the Company had demonstrated compliance with the alternative minimum shareholders' equity requirement of $2.5 million set forth in Nasdaq Listing Rule 5550(b)(1), giving effect to the completion of the transactions described in the Company's Current Report on Form 8-K filed with the SEC on November 16, 2026. The Conditional Compliance Notice stated that the Company's compliance is conditioned upon the Company evidencing continued compliance with the minimum shareholders' equity requirement in its next periodic report for the period ending December 31, 2026. If the Company does not evidence compliance with the minimum shareholders' equity requirement in that report, the Company may be subject to delisting from Nasdaq. There can be no assurance that the Company will be able to maintain compliance with the minimum shareholders' equity requirement, that Nasdaq will determine that the Company has satisfied the condition set forth in the Conditional Compliance Notice or that the Company will be able to maintain compliance with Nasdaq's other continued listing requirements in the future.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 19, 2026, the Company issued a press release regarding the matters described in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01. The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.